Pharmaceutical Executive October 19, 2023

Transaction valued at approximately $3.1 billion.

Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. The transaction, which is expected to be finished by mid-2024, is valued at an estimated 3.1 billion which includes net cash of approximately $143 million.

Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. The transaction, which is expected to be finished by mid-2024, is valued at an estimated 3.1 billion...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Precision Medicine, Trends
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article